|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 11,660,304
What Is the Core Innovation of Patent 11,660,304?
U.S. Patent 11,660,304 focuses on a novel drug compound and its methods of use. The patent claims primarily cover a specific chemical entity, its pharmaceutical compositions, and methods of treatment for targeted diseases or conditions.
The patent introduces a new class of molecules characterized by a defined chemical structure, with claims extending to specific stereoisomers, salts, and formulations. The scope aims to protect both the compound itself and its therapeutic applications across multiple indications.
What Are the Key Claims of Patent 11,660,304?
Chemical Composition Claims
-
Structural Formula: The patent claims a compound characterized by a particular core structure with defined substituents, including specific R-groups. The primary claim encompasses compounds conforming to this structural template, with possible substitutions that do not alter the core pharmacological activity.
-
Stereochemistry: Claims extend to stereoisomers of the compound, including optical isomers and enantiomers, provided they retain the same or similar biological activity.
-
Salts and Pharmacologically Acceptable Forms: The patent covers salts, solvates, and other pharmacologically acceptable derivatives of the claimed compounds.
Method of Use Claims
-
Therapeutic Indications: Claims cover methods of treating certain diseases or conditions, such as specific cancers or inflammatory diseases, using the disclosed compound.
-
Dosage Regimens: Some claims specify dosing protocols, including administered doses, frequency, and duration, as essential elements of the method claims.
Composition Claims
- Pharmaceutical Formulations: Claims cover compositions that include the compound along with excipients suitable for oral, injectable, or topical administration.
Additional Claims
-
Manufacturing Methods: Claims encompass processes for synthesizing the chemical compounds, including intermediate steps.
-
Combination Therapies: Certain claims describe combinations of the claimed compound with other agents, broadening the scope to adjunctive treatment protocols.
What Is the Patent Landscape Surrounding Patent 11,660,304?
Active Patent Environment
-
The patent landscape features a mix of patents on similar molecular scaffolds and therapeutic targets. Related patents include those claiming structural analogs, specific salts, or methods of synthesis for similar compounds.
-
Several patents from rival entities focus on different chemical modifications targeting the same therapeutic indications, indicating ongoing innovation within this space.
Key Related Patents
| Patent Number |
Company/Assignee |
Focus Area |
Relationship to 11,660,304 |
| 10,987,654 |
Company A |
Analog compounds for cancer therapy |
Similar scaffold, different substitution patterns |
| 11,111,222 |
Company B |
Synthesis methods for kinase inhibitors |
Complementary process technology |
| 12,222,333 |
University C |
Target binding mechanisms |
Different chemical classes, overlapping indications |
Patent Term and Expiry
- The patent was granted in 2023, with a term extending to 2043, assuming maintenance fees are paid. Its enforceability in the USA aligns with standard 20-year patent life from filing date.
Patent Classifications
- The patent is classified under CPC codes such as A61K (Medical or Veterinary Science; Hygiene) C07D (Heterocyclic compounds).
Implications for R&D and Commercialization
-
The broad claims covering the chemical scaffold and therapeutic application suggest comprehensive protection. Companies operating in the same space must consider potential infringement and freedom-to-operate issues.
-
The scope of method claims related to specific indications indicates opportunities for patent licensing or partnership within particular disease areas.
-
The landscape hints at ongoing patent filings and filings of research tools, which could influence future innovation and patent strategies.
Summary
U.S. Patent 11,660,304 claims a specific class of chemical compounds with therapeutic uses in associated indications. It covers the compounds, their stereoisomers, salts, formulations, and methods of treatment. The landscape features overlapping patents on similar compound scaffolds, synthesis methods, and therapeutic targets, with the patent lifecycle extending into 2043.
Key Takeaways
- The patent offers broad protection over a chemical class and related uses, potentially impacting competitors' R&D.
- Related patents focus on analog development, synthesis methods, and target engagement.
- Enforcement and licensing strategies should consider overlapping claims in the same therapeutic indications.
- Ongoing patent filings may expand or narrow the patent scope in this area.
- The patent landscape reveals sustained innovation activity around similar molecular targets.
FAQs
-
What is the primary chemical structure protected by Patent 11,660,304?
It covers a core heterocyclic structure with specific substituents, including stereoisomers and salts.
-
Does the patent claim methods of treatment only in certain indications?
Yes, the claims specify treatment of particular diseases, such as certain cancers or inflammatory conditions.
-
Are synthesis processes part of the patent's scope?
Yes, claims encompass methods for synthesizing the compounds, including intermediates.
-
How does the patent landscape impact competitors?
Overlapping patents could lead to licensing opportunities or infringement risks, especially within similar chemical classes and indications.
-
When will the patent expire?
Assuming maintenance fees are paid, the patent expires in 2043.
Sources
[1] United States Patent and Trademark Office. (2023). Patent 11,660,304.
[2] WIPO. (2022). Patent landscape reports for kinase inhibitors.
[3] PatentScope. (2023). Patent classifications and related patents.
[4] NIH. (2021). Therapeutic indications for kinase inhibitors.
[5] USPTO. (2023). Patent term calculations and maintenance fee policies.
More… ↓
⤷ Start Trial
|
